186
Participants
Start Date
April 30, 2008
Primary Completion Date
June 30, 2009
Study Completion Date
July 31, 2009
Lymphoseek
Breast Cancer: Intradermal admin of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2-.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2-0.4 in multiple divided injections or a single injection in subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0-4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma pts intradermal administration of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.
Thomas Frazier, M.D., Bryn Mawr
Ned Carp, M.D., Philadelphia
Eli Avisar, M.D., Miami
Charles Cox, M.D., Tampa
Vernon Sondak, M.D., Tampa
Barbara Michna, M.D, Alexander City
Helen Krontiras, M.D., Birmingham
Stephen Povoski, M.D., Columbus
Julian Kim, M.D., Cleveland
Bruce Averbook, M.D, Cleveland
Schlomo Schneebaum, M.D., Tel Aviv
Mark Faries, M.D., Santa Monica
Anne Wallace, M.D., La Jolla
Ken Deck, M.D., Laguna Hills
Steve Martinez, M.D., Sacramento
Lead Sponsor
Navidea Biopharmaceuticals
INDUSTRY